JP2022534788A5 - - Google Patents

Info

Publication number
JP2022534788A5
JP2022534788A5 JP2021571896A JP2021571896A JP2022534788A5 JP 2022534788 A5 JP2022534788 A5 JP 2022534788A5 JP 2021571896 A JP2021571896 A JP 2021571896A JP 2021571896 A JP2021571896 A JP 2021571896A JP 2022534788 A5 JP2022534788 A5 JP 2022534788A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
approximately
compound
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021571896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036137 external-priority patent/WO2020247643A1/en
Publication of JP2022534788A publication Critical patent/JP2022534788A/ja
Publication of JP2022534788A5 publication Critical patent/JP2022534788A5/ja
Priority to JP2025101917A priority Critical patent/JP2025138706A/ja
Pending legal-status Critical Current

Links

JP2021571896A 2019-06-07 2020-06-04 Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 Pending JP2022534788A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025101917A JP2025138706A (ja) 2019-06-07 2025-06-18 Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07
US62/858,837 2019-06-07
PCT/US2020/036137 WO2020247643A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025101917A Division JP2025138706A (ja) 2019-06-07 2025-06-18 Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態

Publications (2)

Publication Number Publication Date
JP2022534788A JP2022534788A (ja) 2022-08-03
JP2022534788A5 true JP2022534788A5 (cg-RX-API-DMAC7.html) 2023-06-07

Family

ID=71787182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571896A Pending JP2022534788A (ja) 2019-06-07 2020-06-04 Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態
JP2025101917A Pending JP2025138706A (ja) 2019-06-07 2025-06-18 Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025101917A Pending JP2025138706A (ja) 2019-06-07 2025-06-18 Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態

Country Status (15)

Country Link
US (2) US11220501B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980128A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022534788A (cg-RX-API-DMAC7.html)
KR (1) KR20220019017A (cg-RX-API-DMAC7.html)
CN (2) CN114190090A (cg-RX-API-DMAC7.html)
AU (1) AU2020288631A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022635A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142430A1 (cg-RX-API-DMAC7.html)
IL (1) IL288568A (cg-RX-API-DMAC7.html)
MA (1) MA56113A (cg-RX-API-DMAC7.html)
MX (1) MX2021014855A (cg-RX-API-DMAC7.html)
PH (1) PH12021552902A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112461QA (cg-RX-API-DMAC7.html)
TW (1) TW202112785A (cg-RX-API-DMAC7.html)
WO (1) WO2020247643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) * 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
KR20200143417A (ko) 2018-04-10 2020-12-23 레볼루션 메디슨즈, 인크. Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Similar Documents

Publication Publication Date Title
JP7447071B2 (ja) 固体形態
CN116685326A (zh) Cdk抑制剂的共晶体
CN115916749B (zh) α-1抗胰蛋白酶调节剂
JP2022526438A5 (cg-RX-API-DMAC7.html)
JP2007521340A5 (cg-RX-API-DMAC7.html)
HUT71593A (en) Diketopiperazines, pharmaceutical compositions containing and process for producing the compounds
JP4142621B2 (ja) 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法
JP2006528973A5 (cg-RX-API-DMAC7.html)
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
JP2008513358A5 (cg-RX-API-DMAC7.html)
JP2020521732A5 (cg-RX-API-DMAC7.html)
JP6937322B2 (ja) 置換ピペリジン化合物の塩
CN109937200B (zh) 一种苯并呋喃类衍生物游离碱的晶型及制备方法
CN101243066A (zh) 甲磺酸伊马替尼的δ和ε晶形
JP2012508719A (ja) スニチニブマレートの新たな結晶形
JP2023541434A5 (cg-RX-API-DMAC7.html)
JP2021535111A5 (cg-RX-API-DMAC7.html)
JP2022523368A5 (cg-RX-API-DMAC7.html)
CN102264726A (zh) 新的舒尼替尼盐
JP2022540922A5 (cg-RX-API-DMAC7.html)
JP2024525145A5 (cg-RX-API-DMAC7.html)
JP2023521411A5 (cg-RX-API-DMAC7.html)
JP2022535850A5 (cg-RX-API-DMAC7.html)
JP2025516683A5 (cg-RX-API-DMAC7.html)
JP2024518429A5 (cg-RX-API-DMAC7.html)